Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.74 |
| ▸ | GLA | P06280 | 1/20 | 0.74 |
| ▸ | POLB | P06746 | 4/20 | 0.73 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.70 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.64 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.64 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.64 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.64 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.64 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.64 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.64 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.64 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.64 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.64 |
| ▸ | BCHE | P06276 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3240726 | 0.95 | MAPT (0.68) | MAPTGLAPOLBCYP1A1HDAC3 | |
| SCHEMBL14578751 | 0.92 | POLB (0.85) | MAPTGLAPOLBHDAC3HDAC1 | |
| SCHEMBL8737500 | 0.92 | POLB (0.84) | MAPTGLAPOLBCYP1A1HDAC3 | |
| SCHEMBL27874786 | 0.90 | KMT2A (0.77) | MAPTGLAPOLBCYP1A1HDAC3 | |
| SCHEMBL7825018 | 0.89 | POLB (0.70) | MAPTGLAPOLBCYP1A1HDAC3 | |
| SCHEMBL1064449 | 0.87 | HDAC1 (0.76) | MAPTGLAPOLBHDAC3HDAC1 | |
| SCHEMBL6173694 | 0.85 | CYP1A1 (0.70) | MAPTGLAPOLBCYP1A1BCHE | |
| SCHEMBL10087214 | 0.85 | POLB (0.73) | MAPTGLAPOLBHDAC3HDAC1 | |
| SCHEMBL3229329 | 0.84 | NPC1 (0.64) | MAPTGLAPOLBCYP1A1HDAC3 | |
| SCHEMBL8141141 | 0.84 | POLB (0.80) | MAPTGLAPOLBHDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3777898-A2 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | Endocyte, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| US-20190275181-A1 | Compounds for Positron Emission Tomography | ENDOCYTE INC (US) | 2019-09-12 | — | — | US | disclosed |
| EP-3533473-A2 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | Endocyte, Inc. (US) | 2019-09-04 | — | — | EP | disclosed |
| WO-2017051355-A1 | COMPOUNDS WITH HIV MATURATION INHIBITORY ACTIVITY | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-03-30 | — | — | WO | disclosed |
| WO-2017017607-A1 | BETUIN DERIVATIVES FOR PREVENTING OR TREATING HIV INFECTIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-02-02 | — | — | WO | disclosed |
| US-20160287731-A1 | Compounds for Positron Emission Tomography | ENDOCYTE, INC | 2016-10-06 | — | — | US | disclosed |
| WO-2015073678-A1 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | ENDOCYTE, INC. (US) | 2015-05-21 | — | — | WO | disclosed |
| US-20140128352-A1 | COMPOUNDS AND METHODS FOR MODULATING MITOCHONDRIAL METABOLISM AND REACTIVE OXYGEN SPECIES PRODUCTION | BUCK INSTITUTE FOR RESEARCH ON AGING (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140128352-A1 | COMPOUNDS AND METHODS FOR MODULATING MITOCHONDRIAL METABOLISM AND REACTIVE OXYGEN SPECIES PRODUCTION | BUCK INSTITUTE FOR RESEARCH ON AGING (US) | 2014-05-08 | — | — | US | disclosed |
| US-8501754-B2 | Quinazolinamide derivatives | MERCK PATENT GMBH (DE) | 2013-08-06 | — | — | US | disclosed |
| US-8153660-B2 | Piperidyl-propane-thiol CCR3 modulators | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-10 | — | — | US | disclosed |
| US-7959990-B2 | Adjustment of liquid crystals; oligomers, dendrimers, or polymer in solution is applied to support; crosslinking by radiation or polarized light | ROLIC AG (CH) | 2011-06-14 | — | — | US | disclosed |
| US-20100317634-A1 | PIPERIDYL-PROPANE-THIOL CCR3 MODULATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-16 | — | — | US | disclosed |
| US-20100234324-A1 | Quinazolinamide derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-16 | — | — | US | disclosed |
| US-7736624-B2 | derivatives of non-steroidal anti-inflammatory drugs that exhibit selective binding to cyclooxygenase-2 (COX-2) and that comprise functional groups allowing them to be used for medical diagnosis and/or as therapeutic agents; tissue-targeted therapy | UNIV VANDERBILT (US) | 2010-06-15 | — | — | US | disclosed |
| US-7517996-B2 | Azole compound | AJINOMOTO CO., INC. (JP) | 2009-04-14 | — | — | US | disclosed |
| US-20080274304-A1 | Functionalized Photoreactive Compounds | ROLIC AG (CH) | 2008-11-06 | — | — | US | disclosed |
| US-20070292352-A1 | derivatives of non-steroidal anti-inflammatory drugs that exhibit selective binding to cyclooxygenase-2 (COX-2) and that comprise functional groups allowing them to be used for medical diagnosis and/or as therapeutic agents; tissue-targeted therapy | VANDERBILT UNIVERSITY (US) | 2007-12-20 | — | — | US | disclosed |
| US-7196080-B2 | Respiratory system disordeers; chronic obstructive pulminary disease | ASTELLAS PHARMA INC. (JP) | 2007-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190275181-A1 | Compounds for Positron Emission Tomography | FOLH1, FOLR2, FOLR1 | MAPT 883/4885GLA 527/4885POLB 388/4885 |
| US-20080274304-A1 | Functionalized Photoreactive Compounds | PCNA, PIN1, MAP1LC3C | MAPT 1166/4885GLA 3166/4885POLB 610/4885 |
| US-20100317634-A1 | PIPERIDYL-PROPANE-THIOL CCR3 MODULATORS | CCR3, CCR1, CCRL2 | MAPT 3205/4885GLA 4881/4885POLB 4415/4885 |
| US-20140128352-A1 | COMPOUNDS AND METHODS FOR MODULATING MITOCHONDRIAL METABOLISM AND REACTIVE OXYGEN SPECIES PRODUCTION | PC, PCK2, TXNRD2 | MAPT 2501/4885GLA 1238/4885POLB 761/4885 |
| US-20160287731-A1 | Compounds for Positron Emission Tomography | FOLH1, FOLR2, FOLR1 | MAPT 883/4885GLA 527/4885POLB 388/4885 |
| US-20100234324-A1 | Quinazolinamide derivatives | HSP90AB1, HSP90AA1, HSP90AB2P | MAPT 1744/4885GLA 4074/4885POLB 3667/4885 |
| US-20070292352-A1 | derivatives of non-steroidal anti-inflammatory drugs that exhibit selective binding to cyclooxygenase-2 (COX-2) and that comprise functional groups allowing them to be used for medical diagnosis and/or as therapeutic agents; tissue-targeted therapy | PTGES2, PTGS2, PTGER2 | MAPT 2603/4885GLA 1144/4885POLB 3293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.